China has achieved a significant breakthrough in medical technology by successfully producing Yttrium-90 in a commercial nuclear reactor at the Qinshan Nuclear Power Base. This advancement, announced by the China National Nuclear Corporation (CNNC), positions China as a leader in advanced isotope manufacturing, aimed at improving cancer treatment options, particularly for liver tumors. The domestically produced Yttrium-90 microspheres offer a targeted, minimally invasive treatment method that delivers precise radiation to cancer cells while sparing surrounding healthy tissue. Previously, China relied on imported Yttrium-90, which posed challenges for accessibility and affordability for patients. The successful production of Yttrium-90, now meeting all quality standards, is expected to enhance the availability of this treatment, potentially revolutionizing cancer care and improving patient outcomes globally. This achievement not only highlights China's growing capabilities in nuclear medicine but may also inspire international collaboration in the field as countries seek more effective cancer therapies.
Sun, 22 Jun 2025 11:00:03 GMT | Sustainability Times